Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Revenue of Profound Medical Corp. (PROF)
Revenue in 2023 (TTM): $7.33 M
According to Profound Medical Corp.'s latest financial reports the company's current revenue (TTM) is $7.33 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Profound Medical Corp.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $7.33 M | $4.51 M | $-27,123,454 | $-29,223,268 | $-28,569,000 |
| 2022 | $6.68 M | $3.02 M | $-26,604,000 | $-28,382,000 | $-28,669,000 |
| 2021 | $6.87 M | $2.95 M | $-28,648,000 | $-30,594,000 | $-30,699,000 |
| 2020 | $7.3 M | $3.47 M | $-19,496,000 | $-21,577,000 | $-21,622,000 |
| 2019 | $4.23 M | $2.42 M | $-12,526,000 | $-15,309,527 | $-15,457,945 |
| 2018 | $1.91 M | $604.82 K | $-13,242,418 | $-15,074,708 | $-15,244,150 |
| 2017 | $3.9 M | $1.49 M | $-13,226,149 | $-14,909,120 | $-14,968,065 |
| 2016 | $ | $ | $-15,494,147 | $-12,136,534 | $-12,146,990 |
| 2015 | $ | $ | $-11,148,076 | $-12,323,943 | $-11,800,720 |
| 2014 | $ | $ | $-4,253,861 | $-7,937,016 | $-8,204,409 |